Table 1.
Selected treatment regimens for transplant eligible newly diagnosed multiple myeloma.
| Clinical trial | Number of patients | Treatment regimen | Median age (years) | Median follow up (months) | Progression-free survival (months) |
|---|---|---|---|---|---|
| 4 drug vs 3 drugs | |||||
| GMMG-HD752 | 660 | Isa-RVD vs. RVD | 59 | 4.2 | N/A |
| GRIFFIN53,54 | 207 | Dara-RVD vs. RVD | 60 | 49.6 | NR for both groups |
| CASSIOPEIA55 | 1085 | Dara-VTD vs. VTD | 58.5 | 35.4 | NR vs. 46.7 |
| 3 drug combinations | |||||
| DETERMINATION51 | 357 | RVD vs RVD + HSCT | 57 vs 55 | 76 | 46.2 vs 67.5 |
| Myeloma XI56 | 2042 | CRD-HSCT vs CTD-HSCT | 61 | 36.3 | 36 vs 33 |
| FORTE57 | 474 | KRd-HSCT vs KCd-HSCT | 57 | 50.9 | NR vs 53 |
| IFM-DFCI42 | 700 | RVD-HSCT vs RVD | 59 | 43 | 50 vs 36 |
Abbreviations: Isa-RVD, isatuximab, lenalidomide, bortezomib, dexamethasone; Dara-RVD, daratumumab, lenalidomide, bortezomib, dexamethasone; Dara-VTD, daratumumab, bortezomib, thalidomide, dexamethasone; RVD, lenalidomide, bortezomib, dexamethasone; HSCT, hematopoietic stem cell transplant; CRD, cyclophosphamide, lenalidomide, dexamethasone; CTD; cyclophosphamide, thalidomide, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; KCd, carfilzomib, cyclophosphamide, dexamethasone; HSCT, hematopoietic stem cell transplant; NR, not reached; N/A, not available.